Increased proportions of CD3+CD8+, CD25+, and CD3+CD56+ cells in peripheral blood up to 108 d after immunotherapy; median HBV viral load decreased from to copies of DNA/mL in 3 months
CIK cells can efficiently improve the immunological status of HCC patients; CIK cells played important role in antiviral and antitumoral treatment
TACE/RFA; immunotherapy group: additional CIK infusions i.v. or via hepatic artery
After 1 yr followup: 29 of 33 patients in immunotherapy group and 23 of 31 patients in control group were recurrence-free; in 29 patients in the immunotherapy group and in only 1 patient in the control group the HBV DNA content was <1 × 103
CIK therapy can prolong the recurrence-free time and fight HBV; CIK therapy after TACE/RFA is an effective therapeutic strategy for HCC
TACE/RFA; immunotherapy group: additional CIK infusions via hepatic artery
Increased proportions of CD3+, CD4+, CD56+, and CD3+CD56+ cells and the CD4+/CD8+ ratio—percentages were lower in recurrent patients than in nonrecurrent patients; recurrence: 31.1% in immunotherapy group versus 85.0% in control group
CIK cell therapy can reduce recurrence and improve survival rates; CIK transfusions can boost immunity of HCC patients
TACE/RFA; immunotherapy group: additional CIK cell transfusions i.v. or via common hepatic artery
Downtrend of AFP only in immunotherapy group; 1-yr recurrence rate 7.14% in immunotherapy group versus 23.1% in control group; percentage of patients with HBV DNA content <1 × 103 copies/mL was 73.5% in the immunotherapy group versus 9.1% in the control group
CIK cell transfusions can decrease the 1-yr recurrence rate of HCC patients and reduce serum AFP levels, which may serve as a useful marker to predict clinical outcome after immunotherapy and TACE/RFA
TACE; immunotherapy group: additional i.v. CIK cell transfusions
1-yr and 2-yr PFS rates: 40.4% and 25.3% in the immunotherapy group versus 7.7% and 2.6% in the control group; 1-yr and 2-yr OS rates: 71.9% and 62.4% in the immunotherapy group versus 42.8% and 18.8% in the control group; the times of TACE and CIK cell transfusions were independent prognostic factors for PFS and OS
Adjuvant CIK cell therapy can greatly improve the efficacy of TACE and prolong PFS and OS in HCC patients
Significant increases in levels of CD4+, CD3+CD8+, and CD3+CD56+ cells in peripheral blood; AFP and abdominal circumference decreased; median TTP: 6.1 mo; 1-yr survival rate: 17.4%; median OS: 8.5 months
I.p. perfusions of CIK cells combined with local RF hyperthermia are safe, can improve immunology, and prolong survival of HCC patients
Resection; immunotherapy group I: additional 3 courses of CIK therapy; immunotherapy group II: additional 6 courses of CIK therapy
DFS rates significantly higher in CIK-treated groups than in control group; no statistical significance between immunotherapy group I and group II; no statistical significance in OS between the 3 groups
Postoperative CIK cell therapy can prolong DFS but not the OS rates; valuable therapeutic strategy for HCC patients to prevent recurrence
Resection, radio-, chemo-, and interventional therapies; immunotherapy group: additional transfusion of CIK cells previously cocultured with α-Gal epitope-pulsed DCs
Survival was significantly prolonged: 17.1 months in the immunotherapy group versus 10.1 months in the control group; all patients in the immunotherapy group had systemic cytotoxicity in response to tumor lysate, decreased serum AFP, and increased levels of CD8+, CD45RO+, and CD56+ cells in peripheral blood
CIK therapy was safe and effective; new therapeutic approach has great potential in tumor therapy